5 papers in the library · 13 citations · publishing 2024-2026
BJPsych Open May 13, 2026 Zeina Beidas, Anya Ragnhildstveit, Adam Blackman et al.
Microdosing psilocybin for major depressive disorder: study protocol for a phase II double-blind placebo-controlled randomised partial crossover trial - CORRIGENDUM.
BJPsych Open February 16, 2026 Zeina Beidas, Anya Ragnhildstveit, Adam Blackman et al. 1 citation
BACKGROUND: Major depressive disorder (MDD) is the leading cause of disability worldwide, affecting roughly 322 million people. Recently, doses of psilocybin have shown promise in treating mood disorders, sparking interest in other dosing practices. According to anecdotal reports and observational studies, microdosing psilocybin yields benefits to mental health; however, rigorously controlled...
November 16, 2025 Zeina Beidas, Anya Ragnhildstveit, Adam Blackman et al. preprint
Background: Major depressive disorder (MDD) is the leading cause of disability worldwide, affecting roughly 322 million people. Recently, doses of psilocybin have shown promise in treating mood disorders, sparking interest in other dosing practices. According to anecdotal reports and observational studies, microdosing psilocybin yields benefits to mental health; however, rigorously controlled...
Journal of Psychoactive Drugs December 24, 2024 Omer A. Syed, Rotem Petranker, Emily C. Fewster et al. 3 citations
Although several studies have well described the characteristics of people who use psychedelics alongside their motivations and beliefs, little research has examined the preferences surrounding the source of psychedelic substances. In an anonymous online survey, we collected data from 6,379 consumers of 11 different psychedelic substances from 85 different countries, exploring their preferences...
Journal of Psychoactive Drugs November 6, 2024 Rotem Petranker, Valentyn Sobolenko, Zeina Beidas et al. 9 citations
Despite psychedelic microdosing being a growing practice, the research on the topic is still in its infancy. While several studies have described the characteristics, motivations and practices of microdosers, the differences between individuals that only microdose and those that use both micro and macrodoses of psychedelics remain unexplored. In an online survey, we collected data of 6193...